Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease

Metabolism: Clinical and Experimental

Volumn 60, Issue 6, 2011, Pages 776-781

  Kasumov, Takhar ^a   Edmison, John M ^a   Dasarathy, Srinivasan ^a   Bennett, Carole ^a   Lopez, Rocio ^a   Kalhan, Satish C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 N,N' DIMETHYLARGININE; HOMOCYSTEINE; N(G),N(G) DIMETHYLARGININE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER BIOPSY; LIVER DYSFUNCTION; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; ARGININE; BIOPSY; BLOOD GLUCOSE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FATTY LIVER; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INSULIN RESISTANCE; LIVER; MALE; MIDDLE AGED;

EID: 79956063329     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2010.07.027     Document Type: Article

References (35)

1. McBride AE, Silver PA. State of the arg: protein methylation at arginine comes of age. Cell 2001;106:5-8. (Pubitemid 32709951)
2. Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992;20:S60-2.
3. Leiper J, Nandi M, Torondel B, et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nature Med 2007;13:198-203.
4. Boger RH, Bode-Boger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998;98:1842-7. (Pubitemid 28509278)
5. Horowitz JD, Heresztyn T. An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: methodological considerations. J Chromatogr B Analyt Technol Biomed Life Sci 2007;851:42-50. (Pubitemid 46720137)
6. Siroen MP, Teerlink T, Nijveldt RJ, Prins HA, Richir MC, Van Leeuwen PA. The clinical significance of asymmetric dimethylarginine. Annu Rev Nutr 2006;26:203-28.
7. Richir MC, Bouwman RH, Teerlink T, et al. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function. J Parent Ent Nutr 2008;32:613-21.
8. Dayal S, Lentz SR. ADMA and hyperhomocysteinemia. Vasc Med 2005;10:S27-S33. (Pubitemid 43137265)
9. Tyagi N, Sedoris KC, Steed M, Ovechkin AV, Moshal KS, Tyagi SC. Mechanisms of homocysteine-induced oxidative stress. Am J Physiol Heart Circ Physiol 2005;289:H2649-56.
10. Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function - a meta-analysis. Nephrol Dial Transplant 2006;21:2446-51. (Pubitemid 44644516)
11. Sydow K, Mondon CE, Cooke JP. Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA. Vasc Med 2005;10:S35-S43. (Pubitemid 43137266)
12. Abbasi F, Asagmi T, Cooke JP, et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001;88:1201-3. (Pubitemid 33043860)
13. Altinova AE, Arslan M, Sepici-Dincel A, Akturk M, Altan N, Toruner FB. Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations. J Clin Endocrinol Metab 2007;92:1881-5. (Pubitemid 46997204)
14. McLaughlin T, Stuhlinger M, Lamendola C, et al. Plasma asymmetric dimethylarginine concentrations are elevated in obese insulin-resistant women and fall with weight loss. J Clin Endocrinol Metab 2006;91:1896-900.
15. Tsikas D, Rode I, Becker T, Nashan B, Klempnauer J, Frolich JC. Elevated plasma and urine levels of ADMA and 15(S)-8-iso- PGF2alpha in end-stage liver disease. Hepatology 2003;38:1063-4. (Pubitemid 37229063)
16. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006;40:S17-S29. (Pubitemid 44309539)
17. Videla LA, Rodrigo R, Orellana M, et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci (Lond) 2004;106:261-8. (Pubitemid 38365832)
18. Sydow K, Munzel T. ADMA and oxidative stress. Atheroscler Suppl 2003;4:41-51. (Pubitemid 38234494)
19. Kleiner DE, Brunt EM, Van NM, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21. (Pubitemid 40770284)
20. Borch-Johnsen K. The new classification of diabetes mellitus and IGT: a critical approach. Exp Clin Endocrinol Diabetes 2001;109:S86-S93. (Pubitemid 32577573)
21. Teerlink T, Nijveldt RJ, de JS, Van Leeuwen PA. Determination of arginine, asymmetric dimethylarginine, and symmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem 2002;303:131-7. (Pubitemid 34407576)
22. Marra M, Bonfigli AR, Testa R, Testa I, Gambini A, Coppa G. High-performance liquid chromatographic assay of asymmetric dimethylarginine, symmetric dimethylarginine, and arginine in human plasma by derivatization with naphthalene-2,3-dicarboxaldehyde. Anal Biochem 2003;318:13-7. (Pubitemid 36627477)
23. Hermans MP, Levy JC, Morris RJ, Turner RC. Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia 1999;42:678-87. (Pubitemid 29265585)
24. Garcia AJ, Apitz-Castro R. Plasma total homocysteine quantification: an improvement of the classical high-performance liquid chromatographic method with fluorescence detection of the thiol-SBD derivatives. J Chromatogr B 2002;779:359-63. (Pubitemid 35279464)
25. Nelson AW, Mackinnon B, Traynor J, Geddes CC. The relationship between serum creatinine and estimated glomerular filtration rate: implications for clinical practice. Scott Med J 2006;51:5-9. (Pubitemid 46029597)
26. Marliss EB, Chevalier S, Gougeon R, et al. Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover. Diabetologia 2006;49:351-9. (Pubitemid 43185404)
27. Schwedhelm E. Quantification of ADMA: analytical approaches. Vasc Med 2005;10:S89-S95. (Pubitemid 43137272)
28. Martens-Lobenhoffer J, Krug O, Bode-Boger SM. Determination of arginine and asymmetric dimethylarginine (ADMA) in human plasma by liquid chromatography/mass spectrometry with the isotope dilution technique. J Mass Spectrom 2004;39:287-94.
29. Martens-Lobenhoffer J, Bode-Böger SM. Chromatographic-mass spectrometric methods for the quantification of L-arginine and its methylated metabolites in biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci 2007;851:30-41. (Pubitemid 46720133)
30. Nijveldt RJ, Teerlink T, Siroen MP, et al. Elevation of asymmetric dimethylarginine (ADMA) in patients developing hepatic failure after major hepatectomy. J Parenter Enteral Nutr 2004;28:382-7. (Pubitemid 39463821)
31. Vizzutti F, Romanelli RG, Arena U, et al. ADMA correlates with portal pressure in patients with compensated cirrhosis. Eur J Clin Invest 2007;37:509-15. (Pubitemid 46817349)
32. Martin-Sanz P, Olmedilla L, Dulin E, et al. Presence of methylated arginine derivatives in orthotopic human liver transplantation: relevance for liver function. Liver Transpl 2003;9:40-8. (Pubitemid 36104914)
33. Mookerjee RP, Malaki M, Davies NA, et al. Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. Hepatology 2007;45:62-71. (Pubitemid 46144365)
34. Stülinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001;104:2569-75. (Pubitemid 33104795)
35. Teerlink T. Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevance. Clin Chem Lab Med 2005;43:1130-8. (Pubitemid 41581973)